Corbett and Daniel A. Pelak Join Board of Directors in Preparation for Launch of MILD(TM), an Innovative, Minimally Invasive Spinal Treatment
Procedure
SAN JOSE, Calif., Nov. 7 /PRNewswire/ -- Vertos Medical, Inc., a privately held medical device manufacturer focusing on a minimally invasive treatment for Lumbar Spinal Stenosis (LSS), today announced that the company has appointed James M. Corbett as its President and Chief Executive Officer and to its Board of Directors. In addition, the company announced it has expanded its Board to include Daniel A. Pelak. Corbett and Pelak bring decades of senior management experience in the development and commercialization of innovative medical devices. Vertos Medical, which has U.S. Food and Drug Administration (FDA) clearance for its MILD(TM) (Minimally Invasive Lumbar Decompression) technology, recently initiated an Institutional Review Board - controlled clinical trial called the Vertos MILD(TM) Preliminary Patient Evaluation Study.
The MILD(TM) procedure is a simple, percutaneous, fluoroscopically guided treatment for Lumbar Spinal Stenosis (LSS). MILD(TM) can be performed under local anesthesia and substantially reduces the tissue damage and removal associated with other minimally invasive or open surgeries. Recent clinical results in 32 patients(1) with moderate-to-severe LSS demonstrated improved mobility and decreased pain. To date, more than 80 patients have undergone the procedure without any adverse events.
In July 2008, Vertos completed a $12 million financing from leading venture capital firms CHL Medical Partners, Foundation Medical Partners, Aweida Ventures, and DFJ Mercury. With the addition of Mr. Corbett and Mr. Pelak, the Vertos Board expands to six members.
"We are delighted by the addition of these two seasoned executives to
the Vertos Medical team. Jim has a proven track record in the medical
device industry and brings demonstrated e
'/>"/>
| SOURCE Vertos Medical, Inc. Copyright©2008 PR Newswire. All rights reserved |